# Sebastian Bauer

Source: https://onco.cc/people/sebastian-bauer/  
OnCo record `sebastian-bauer` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

German sarcoma specialist who was lead author of INTRIGUE, the trial that compared ripretinib with sunitinib as second-line treatment for GIST.

## Summary

Sebastian Bauer leads the sarcoma programme at the West German Cancer Center in Essen. He was first author of the 2022 Journal of Clinical Oncology report of INTRIGUE, the phase 3 trial that found ripretinib was not superior to sunitinib in progression-free survival after imatinib in advanced gastrointestinal stromal tumour, though it was better tolerated. His laboratory studies resistance mechanisms in GIST.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: gist; sarcoma; trialist
- Role: Medical oncologist, West German Cancer Center, University Hospital Essen
- Specialisms: Gastrointestinal stromal tumour; Sarcoma; Kinase inhibitors

## Connected records

- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/), [Imatinib-resistant GIST](https://onco.cc/cancers/gist-imatinib-resistant/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- institutions: [West German Cancer Center (WTZ), University Hospital Essen](https://onco.cc/institutions/essen-wtz/)
- key papers: [INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib](https://onco.cc/key-papers/paper-intrigue-ripretinib-vs-sunitinib-jco-2022/)

---
JSON: https://onco.cc/api/v1/entities/sebastian-bauer.json